AKT1 and Miyoshi myopathy: The co-treatment of bortezomib and miR-29b induces significant anti-MM and pro-apoptotic effects in synthetic miR-29b transient or the stable lentivirus-enforced expression due to the phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathway.